<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:department>Medicine School Office</gtr:department><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/CA194170-5F26-4765-BDDD-216F09FB596E"><gtr:id>CA194170-5F26-4765-BDDD-216F09FB596E</gtr:id><gtr:firstName>Kavita</gtr:firstName><gtr:surname>Raj</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G84%2F6222"><gtr:id>A5305EF1-19B4-4F52-9124-AC8E66588F46</gtr:id><gtr:title>The Function of p15INK4B and RAS in MDS.</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G84/6222</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:fund><gtr:end>2006-08-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2003-06-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>221424</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>9AC47699-3A69-49BD-8D5B-3515E9FF4E2D</gtr:id><gtr:title>CDKN2B methylation status and isolated chromosome 7 abnormalities predict responses to treatment with 5-azacytidine.</gtr:title><gtr:parentPublicationTitle>Leukemia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/174b948f73bede6923dfbe44e3dc5003"><gtr:id>174b948f73bede6923dfbe44e3dc5003</gtr:id><gtr:otherNames>Raj K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0887-6924</gtr:issn><gtr:outcomeId>rqwygvaUCuv</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>842F5211-77CE-44D9-BD4B-20B65BEE12BA</gtr:id><gtr:title>Complete response of deep neutrophilic dermatosis associated with myelodysplastic syndrome to 5-azacytidine.</gtr:title><gtr:parentPublicationTitle>The British journal of dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/174b948f73bede6923dfbe44e3dc5003"><gtr:id>174b948f73bede6923dfbe44e3dc5003</gtr:id><gtr:otherNames>Raj K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0007-0963</gtr:issn><gtr:outcomeId>LEQM3RhPt5H</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>261EE80B-4ADF-405A-B08C-4894D72F70AC</gtr:id><gtr:title>Azacytidine (Vidaza(R)) in the treatment of myelodysplastic syndromes.</gtr:title><gtr:parentPublicationTitle>Therapeutics and clinical risk management</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/174b948f73bede6923dfbe44e3dc5003"><gtr:id>174b948f73bede6923dfbe44e3dc5003</gtr:id><gtr:otherNames>Raj K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1176-6336</gtr:issn><gtr:outcomeId>U3trmV8TiV7</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G84/6222</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>149FA87E-B8CD-4FFC-B515-EAD312BED03B</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Musculoskeletal</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>